chemotherapy-induced peripheral neuropathy
Conditions
Interventions
Sponsors
Guang 'anmen Hospital China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) patients with definite pathological diagnosis of malignant tumors; (2) Patients planned to receive standard chemotherapy based on oxaliplatin and taxane (paclitaxel injection docetaxel paclitaxel liposome albumin paclitaxel). (3) adult patients over 18 years old. (4) ECOG score was 0-2. (5) Informed consent was signed.
Exclusion criteria
Exclusion criteria: (1)Prior chemotherapy with a neurotoxic agent including a taxane oxaliplatin carboplatin cisplatin vinblastine bortezomib or thalidomide. (2) patients with a history of diabetes mellitus peripheral neuropathy caused by other causes or epilepsy. (3) receiving antidepressants or any other medication specifically for the prevention or treatment of neuropathy. (4) coagulation dysfunction or taking anticoagulant drugs. (5) exposed to acupuncture treatment within 3 months before enrollment. (6) patients who are not suitable for acupuncture such as local infection at or near the acupuncture site. (7) patients with psychological or behavioral disorders including schizophrenia or a family history of hereditary/familial neuropathies. (8) women who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of chemotherapy-induced peripheral neuropathy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of CIPN within half a year after completion of chemotherapy;Assessment of pain;Incidence of CIPN after each cycle of chemotherapy;Assessment OF QUALITY OF LIFE;Evaluation OF SAFETY;Quantitative sensory measurement;Medication USE;Fatigue status;Anxiety and depression;Insomnia; | — |
Countries
China
Contacts
Public ContactZHENG Honggang
Guang 'anmen Hospital China Academy of Chinese Medical Sciences
Outcome results
None listed